Trial Profile

Phase II Study of XL184 (Cabozantinib) in Combination With Nivolumab and Ipilimumab (CaboNivoIpi) in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Whose Cancer Progressed After One Prior VEGFR-Targeted Therapy

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 23 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cabozantinib (Primary) ; Cabozantinib (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
Indications Carcinoma; Thyroid cancer
Focus Therapeutic Use

19 Dec 2024 Planned End Date changed from 31 Oct 2024 to 17 Dec 2025.
23 May 2024 Planned End Date changed from 30 Sep 2024 to 31 Oct 2024.
23 May 2024 Planned primary completion date changed from 30 Sep 2024 to 31 Oct 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com